CVS Health

Q3 2026
Speakers

Nov 4, 2026 · 60 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Hello, ?and welcome to CBS Health's third quarter 2026 earnings call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the question and answer session. As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this ?time. I would now like to pass the call to Larry McGrath.

Larry, please proceed.

Passages & reports (6)
  • Hello,
  • and
  • welcome to CBS Health's third quarter 2026 earnings call. We ask that you please hold all …
  • this
  • time.
  • I would now like to pass the call to Larry McGrath. Larry, please proceed.

Speaker 1

Unverified voice label

Good morning, and welcome to the CBS Health Third Quarter 2026 Earnings and Business Update Call and Webcast. ?I'm Larry McGraw, Executive Vice President of Capital Markets at CVS Health. I'm joined this morning by David Joyner, Chairman and Chief Executive Officer, and Brian Newman, Chief Financial Officer. Following our prepared remarks, we'll host a question and answer session that will include additional members of the leadership team.

Our
press releases and slide presentations have been posted to our website along with our Form 10 queue filed this morning with the SEC. Today's call is also being broadcast on our website. During this call, we'll make certain forward looking statements. ?Our forward looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results.

We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties, in particular those that are described in the cautionary statement concerning forward looking statements and
risk factors in our most recent annual report on Form 10K, our quarterly report on Form 10Q filed this morning, and our recent filings on Form 8K, including this morning's earnings press release.

During this call, we'll use certain non-gap measures when talking about the company's financial performance and financial
condition. And you can find a reconciliation of these non-gap measures in this morning's press release ?and in the reconciliation document posted to the investor relations portion of our website. With that, I'd like to turn the call over to David. David?

Passages & reports (10)
  • Good morning, and welcome to the CBS Health Third Quarter 2026 Earnings and Business Updat…
  • I'm
  • Larry McGraw, Executive Vice President of Capital Markets at CVS Health. I'm joined this m…
  • press releases and slide presentations have been posted to our website along with our Form…
  • Our
  • forward looking statements are subject to significant risks and uncertainties that could c…
  • risk factors in our most recent annual report on Form 10K, our quarterly report on Form 10…
  • condition. And you can find a reconciliation of these non-gap measures in this morning's p…
  • and
  • in the reconciliation document posted to the investor relations portion of our website. Wi…

Speaker 2

Unverified voice label

Thank you, Larry, and good morning, everyone. Our organization has a long and distinguished history, and in my 40 years at this company, there has been one constant. We act, we evolve, and we proactively shape the future of healthcare. Today we announced our intention to separate into two independent publicly traded companies. This decision marks the next important chapter in the evolution of CVS Health.

We are creating two distinct leaders in healthcare. The first will be a healthcare solutions company that brings together medical, pharmacy, specialty, and care delivery capabilities integrated where it
matters. ?In the interim period, we are referring to this business as CBS Health. ?The second company will be a leading national retail pharmacy and community healthcare company. This business will be named CBS Pharmacy. Both companies will be led by experienced leadership teams, have a clear right to win in their respective markets, and we expect will be supported by solid investment grade balance sheets, enabling each company to pursue disciplined and tailored capital allocation.

We take this action from a position of strength, which you can see in the consistent progress we made since 2024, as well as in the third quarter results and the updated guidance we announced this morning. This quarter, we generated adjusted operating income of
$4.2 billion and adjusted earnings per share of $2.09. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted earnings per share guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10. ?

We
are also updating our full year expectation for cash flow from operations to at least $15.5 billion. With this latest update, our 2026 adjusted EPS guidance is now more than $1 above our initial expectations for 2026. ?And our cash flow from operations outlook has increased by more than $5.5 billion for the year. This progress clearly reflects our growing momentum. I'll now ask Brian to provide more details on the results this quarter, our updated full year 2026 guidance, and perspective on the factors shaping our 2027 expectations. ?

I
will then come back to provide more details on our announcement. Brian?

Passages & reports (17)
  • Thank you, Larry, and good morning, everyone. Our organization has a long and distinguishe…
  • companies. This decision marks the next important chapter in the evolution of CVS Health. …
  • matters.
  • In
  • the interim period, we are referring to this business as CBS Health.
  • The
  • second company will be a leading national retail pharmacy and community healthcare company…
  • each company to pursue disciplined and tailored capital allocation. We take this action fr…
  • $4.2 billion and adjusted earnings per share of $2.09. Building on our continued strong pe…
  • to $8.10.
  • We
  • are also updating our full year expectation for cash flow from operations to at least $15.…
  • And
  • our cash flow from operations outlook has increased by more than $5.5 billion for the year…
  • expectations.
  • I
  • will then come back to provide more details on our announcement. Brian?

Speaker 3

Unverified voice label

Thank you, David, and good morning. I will cover four key topics in my remarks this morning. First, an update on our third quarter results. Second, I'll discuss cash flow, the balance sheet, and capital deployment. After that, I will provide an updated financial outlook for 2026. And finally, I will share some headwinds and tailwinds as we look ahead to 2027. Our third quarter results demonstrate the discipline with which we continue to manage the enterprise.

We once again delivered on our commitments and raised our full year outlook for revenue, adjusted EPS, and cash flow from operations. Our execution
has significantly strengthened our balance sheet, allowing us to achieve target leverage ahead of schedule and will enable us to resume our share repurchase program in the fourth quarter. ?Let me start by highlighting some of our enterprise results in the quarter.

We generated over $108 billion of revenue and delivered nearly $4.2 billion of adjusted operating income, once again reflecting earnings growth across all of our operating segments.
?We delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. And finally, in the quarter, we generated cash flow from operations of approximately $4.7 billion, bringing our year-to-date cash flow from operations to $15.3 billion.

Turning now to each of our segments in health care benefits, we continue to make strong progress in our return to target margins. In the quarter, we delivered adjusted operating income of approximately $900 million, an increase of nearly $600 million from the prior year
quarter. Our medical benefit ratio was 91.3%, in improvement of approximately 150 basis points from the prior year. These results were primarily driven by improved underlying performance in our Medicare business.

Across our businesses,
we continue to successfully navigate elevated trends that remain above historical levels throughout the industry, but were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations, driven by pockets of favorability as a result of strong medical cost management and discipline pricing. ?We remain confident in the adequacy of our reserves. ?In our health services segment, we continue to execute against our objectives.

During the quarter, we delivered adjusted operating income of $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially
offset by continued pharmacy client price improvements. Results in our pharmacy services business were in line with our expectations during the quarter, including performance in both our 340B business and rebate guarantees. Healthcare delivery also performed as expected as we continue to drive improvement in the business.

Our pharmacy and consumer wellness segment delivered another strong quarter. We generated adjusted operating income of over $1.6 billion, an increase of over 10% from the prior year, primarily driven by core pharmacy strength, including
a nearly 4% increase in same store prescription volumes, partially offset by continued business investments and the impact of consumer dynamics. Turning now to cash flow and the balance sheet, year to date, we have generated cash flow from operations of $15.3 billion, reflecting strong earnings as well as the impact of improvements in working capital.

So far in 2026, we have returned nearly $2.6 billion to our shareholders through our shareholder dividend. We ended the quarter with nearly $6 billion of cash at the parent and
unrestricted subsidiaries. As I mentioned earlier, we have made significant progress strengthening our balance sheet and have achieved our leverage goal ahead of schedule. This improved position, combined with our strong cash flow, will enable us to resume our share repurchase program in the fourth quarter.

Shifting now to our guidance for 2026, we are increasing our full year 2026 guidance for adjusted EPS to at least $8.20, an increase of 20 cents from the midpoint of our previous outlook. We now also expect our full year total
revenues to be at least $420 billion. ?In our health care benefits segment, we now expect full-year adjusted operating income to be at least $5.4 billion, an increase of $200 million relative to the midpoint of our prior outlook.

We now expect our full year MBR to be in the lower half of our previously discussed
range of $89.75%, plus or minus 25 basis points. This outlook continues to maintain a respectful and prudent view of medical cost trends. In our pharmacy and consumer wellness segment, we now expect full year adjusted operating income of at least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% growth from the prior year.

This reflects our strong performance in the quarter and our updated expectations for the remainder of the year. We are also reiterating our full
year adjusted operating income outlook for our health services segment. In aggregate, we now expect full year enterprise adjusted operating income to be at least $17.05 billion. We are also increasing our outlook for full year cash flow from operations to at least $15.5 billion, reflecting our updated earnings outlook as well as the impact of working capital improvements and the timing of certain payments.

Cash generation has long been a strength of this enterprise, and we continue to build on that strength as we deliver on our
embedded earnings and unlock further working capital efficiencies. ?You can find additional details on the components of our updated 2026 guidance on our investor relations website. Turning now to 2027, consistent with past practice, we expect to provide formal 2027 guidance on our fourth quarter earnings call early next year.

Today I will share an update on
some of the key headwinds and tailwinds we are considering for 2027. Starting first with our health care benefits business, we expect another year of meaningful margin improvement as Aetna makes strong progress on its path back to target margins. Once again, this improvement will be largely driven by the deliberate actions we took in our Medicare Advantage business, along with continued disciplined underwriting and pricing across our businesses in response to the elevated trend environment we expect will persist in 2027.

In our health services segment, we expect to generate adjusted operating income of
at least $7 billion. This includes our previously discussed expectations for a year-on-year decline in our 340B business, as well as headwinds from the impact of a less robust selling season and health plan client membership attrition. We also expect tailwinds from continued strength in specialty and another year of improvement in our health care delivery business.

We continue to expect our 340B business to largely stabilize by the end of next year, and we have confidence as we enter the 2028 PBM selling season.
?We are confident 2027 will reflect trough earnings for the segment and we expect to return to growth from there. In our pharmacy and consumer wellness business, we expect adjusted operating income to grow low single digits off our current 2026 guidance of at least $6.5 billion driven by continued pharmacy strength.

This marks the third consecutive year of growth in earnings for this segment. Our updated outlook reflects the progress we've made, differentiating our business and solidifying our position as the best run national pharmacy while maintaining a prudent view
of consumer dynamics. Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline.

Passages & reports (39)
  • Thank you, David, and good morning. I will cover four key topics in my remarks this mornin…
  • tailwinds as we look ahead to 2027. Our third quarter results demonstrate the discipline w…
  • has significantly strengthened our balance sheet, allowing us to achieve target leverage a…
  • Let
  • me start by highlighting some of our enterprise results in the quarter. We generated over …
  • We
  • delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. And …
  • billion. Turning now to each of our segments in health care benefits, we continue to make …
  • quarter. Our medical benefit ratio was 91.3%, in improvement of approximately 150 basis po…
  • we continue to successfully navigate elevated trends that remain above historical levels t…
  • discipline pricing.
  • We
  • remain confident in the adequacy of our reserves.
  • In
  • our health services segment, we continue to execute against our objectives. During the qua…
  • offset by continued pharmacy client price improvements. Results in our pharmacy services b…
  • improvement in the business. Our pharmacy and consumer wellness segment delivered another …
  • a nearly 4% increase in same store prescription volumes, partially offset by continued bus…
  • billion, reflecting strong earnings as well as the impact of improvements in working capit…
  • unrestricted subsidiaries. As I mentioned earlier, we have made significant progress stren…
  • quarter. Shifting now to our guidance for 2026, we are increasing our full year 2026 guida…
  • revenues to be at least $420 billion.
  • In
  • our health care benefits segment, we now expect full-year adjusted operating income to be …
  • range of $89.75%, plus or minus 25 basis points. This outlook continues to maintain a resp…
  • least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% grow…
  • year adjusted operating income outlook for our health services segment. In aggregate, we n…
  • operations to at least $15.5 billion, reflecting our updated earnings outlook as well as t…
  • embedded earnings and unlock further working capital efficiencies.
  • You
  • can find additional details on the components of our updated 2026 guidance on our investor…
  • some of the key headwinds and tailwinds we are considering for 2027. Starting first with o…
  • deliberate actions we took in our Medicare Advantage business, along with continued discip…
  • at least $7 billion. This includes our previously discussed expectations for a year-on-yea…
  • continued strength in specialty and another year of improvement in our health care deliver…
  • We
  • are confident 2027 will reflect trough earnings for the segment and we expect to return to…
  • by continued pharmacy strength. This marks the third consecutive year of growth in earning…
  • of consumer dynamics. Pulling it all together and reflecting the strong performance we saw…

Our strong results demonstrate the progress we're making across the enterprise. We've strengthened our financial position, created greater capacity for capital deployment, and built increased confidence in the long-term expectations we outlined at Investor Day. We now believe we will be in the high end of our mid-teens adjusted EPS CAGR through 2028.

Passages & reports (2)
  • Our strong results demonstrate the progress we're making across the enterprise. We've stre…
  • our mid-teens adjusted EPS CAGR through 2028.

Speaker 3

for outperformance. We will continue delivering on our say due ratio, and that discipline will remain as we progress towards separation. With that, I'll now turn the call back over to David. David?

Passages & reports (1)
  • for outperformance. We will continue delivering on our say due ratio, and that discipline …

Speaker 2

Thank you, Brian. As Brian highlighted, we are executing against our strategy, and our businesses continue to deliver durable results. Today, we announced that we are building on that momentum. CBS Health is taking an important step in its evolution to create two independent publicly traded companies. Each of the two companies will remain a leader in their respective markets, powered by the right assets, the right focus, and the ability to adapt and move faster.

We can take this strategic action today because of our tremendous progress since 2024. We rebuilt our leadership team and instilled a clear culture of accountability,
excellence, and execution across the organization. ?We significantly improved our financial performance, strengthened our balance sheet, and reached our target leverage ratio ahead of schedule, creating capacity for disciplined capital deployment. ?We expanded our technology capabilities across our enterprise, thoughtfully embedding AI throughout our businesses ?and creating a differentiated foundation to simplify and improve the healthcare experience. ?

As
we've consistently demonstrated, we are making great strides delivering against our goals while remaining focused on improving the health and care of the 185 million people we serve. ?As we have advanced our strategy, the environment around us is constantly changing. ?We will be better positioned to address this changing environment as two strong independent health care leaders. Following a thoughtful and deliberate strategic review by the board and senior management, we have a structure and plan that are built to win and represent the best path to create value over the long term.

As we announced,
CBS Health will retain Aetna, CARMARC, and Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health. This enables us to maintain and expand integration where it matters, combining the tools necessary to improve affordability within medical and pharmacy benefits and deliver care to high acuity populations, including in Medicare and specialty pharmacy. CBS Pharmacy will be the leading national retail pharmacy and community healthcare company. ?

It
will include our retail pharmacy stores, Mail Order, Minute Clinic, and Health 100, our AI native integrated healthcare engagement platform for consumers.

Passages & reports (19)
  • Thank you, Brian. As Brian highlighted, we are executing against our strategy, and our bus…
  • Each of the two companies will remain a leader in their respective markets, powered by the…
  • excellence, and execution across the organization.
  • We
  • significantly improved our financial performance, strengthened our balance sheet, and reac…
  • We
  • expanded our technology capabilities across our enterprise, thoughtfully embedding AI thro…
  • and
  • creating a differentiated foundation to simplify and improve the healthcare experience.
  • As
  • we've consistently demonstrated, we are making great strides delivering against our goals …
  • As
  • we have advanced our strategy, the environment around us is constantly changing.
  • We
  • will be better positioned to address this changing environment as two strong independent h…
  • CBS Health will retain Aetna, CARMARC, and Pharmacy Services, Specialty Pharmacy, Oak Stre…
  • high acuity populations, including in Medicare and specialty pharmacy. CBS Pharmacy will b…
  • It
  • will include our retail pharmacy stores, Mail Order, Minute Clinic, and Health 100, our AI…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

rationale for the separation is simple, with four clear benefits. First, focus. Each company will have an experienced, dedicated leadership team that can concentrate on the areas where it has the greatest opportunity to create value. The same mission, sharper focus. Second, capital allocation. Each company is expected to have a solid investment grade capital structure and strong free cash flow. This will enable tailored capital allocation more closely aligned with each company's strategy and growth opportunities.

What will not change is the discipline that each company demonstrates in the deployment of capital. Third is
agility. Each company will have greater flexibility to adopt the technologies that best fit its needs, improve efficiency, and more effectively adapt to the regulatory and other external dynamics. As independent companies, we will innovate and move faster as we work to improve how healthcare is experienced today.

Passages & reports (3)
  • rationale for the separation is simple, with four clear benefits. First, focus. Each compa…
  • Each company is expected to have a solid investment grade capital structure and strong fre…
  • agility. Each company will have greater flexibility to adopt the technologies that best fi…

Finally, and importantly, simplicity. Greater independence will make it easier to serve consumers, members, patients, and communities, ?and will create opportunities for each company to pursue a broader range of partnerships. By taking this deliberate action, we are creating simpler, stronger, and more focused companies. CBS Health will be a scaled health solutions company with attractive growth and strong cash flow generation. This business will preserve a well diversified mix of assets and capabilities to address a $2 plus trillion dollar growing market across Medicare, commercial, and Medicaid. ?

We
will stay relentlessly focused on affordability, access, and health outcomes. I will serve as chairman and CEO alongside the best in class leadership team in place today. CBS Pharmacy will be the national leader in pharmacy and community health care. Our investments in technology and our colleagues continue to set us apart in this greater than a $500 billion market. This is an economically resilient sector where prescription growth will continue to be driven by medical innovation and demographics.

CBS Pharmacy will build on its position as the most trusted and most frequent consumer touch point in healthcare.

Passages & reports (7)
  • Finally, and importantly, simplicity. Greater independence will make it easier to serve co…
  • and
  • will create opportunities for each company to pursue a broader range of partnerships. By t…
  • diversified mix of assets and capabilities to address a $2 plus trillion dollar growing ma…
  • We
  • will stay relentlessly focused on affordability, access, and health outcomes. I will serve…
  • to set us apart in this greater than a $500 billion market. This is an economically resili…

Prem Shaw, currently the group president of CBS Health, ?will become CEO of CBS Pharmacy upon separation. He will be supported by the experienced leaders and colleagues who reset the trajectory and reinvigorated our retail pharmacy business. With attractive growth, enviable cash flow, and a strong balance sheet, CBS Pharmacy will be a unique asset across healthcare and retail. Both companies remain committed to unlocking the tremendous potential of Health 100, our AI native consumer engagement platform. ?

The
mission of Health 100 remains unchanged to be the front door of health and care. ?By focusing on consumers, Health 100 will truly change the way healthcare is experienced in this country. ?We will drive greater interoperability to remove friction from the system and engage with consumers in a way that no one else has ever done before. ?We believe this separation will accelerate the adoption and development of Health 100 and allow us to drive innovation, improve connectivity, and unlock greater value across both companies.

We expect the separation transaction to be tax free for U.S. federal income tax purposes and to be completed in the first half of 2028,
subject to customary conditions, including final board approval, Form 10 effectiveness, and receipt of customary tax confirmation. Following separation, CBS Health shareholders will own shares in both companies. We will be transparent about our progress and we will provide additional details along the way. ?

I
want to emphasize that we will not lose sight ?of the need to execute with excellence every single day and consistently deliver on our commitments to all of our stakeholders. Our purpose is clear: to simplify health care, one person, one family, and one community at a time. I am confident this decision will allow both companies to better deliver on that promise and create lasting value for all stakeholders.

With that, we will now open the call for your questions. Operator?

Passages & reports (18)
  • Prem Shaw, currently the group president of CBS Health,
  • will
  • become CEO of CBS Pharmacy upon separation. He will be supported by the experienced leader…
  • retail. Both companies remain committed to unlocking the tremendous potential of Health 10…
  • The
  • mission of Health 100 remains unchanged to be the front door of health and care.
  • By
  • focusing on consumers, Health 100 will truly change the way healthcare is experienced in t…
  • We
  • will drive greater interoperability to remove friction from the system and engage with con…
  • We
  • believe this separation will accelerate the adoption and development of Health 100 and all…
  • subject to customary conditions, including final board approval, Form 10 effectiveness, an…
  • I
  • want to emphasize that we will not lose sight
  • of
  • the need to execute with excellence every single day and consistently deliver on our commi…
  • that promise and create lasting value for all stakeholders. With that, we will now open th…

Speaker 0

Thank ?you. At this time, if you would like to ask a question, please click on the raise hand button, which can be found on the black bar at the bottom of your screen. When it is your turn, you will receive a message on your screen and then you will hear your name called. Please accept, unmute your audio, and ask your question. ?If you are calling in today, star nine will activate the raised hand feature, and star six can be used to unmute ?and mute your line. ?

We
ask that you please limit yourself to one question this morning. We will wait one moment to allow the queue to form. Our first question will come from the line of Lisa Gill with JP Morgan. Please unmute your line and ask your question.

Passages & reports (10)
  • Thank
  • you.
  • At this time, if you would like to ask a question, please click on the raise hand button, …
  • unmute your audio, and ask your question.
  • If
  • you are calling in today, star nine will activate the raised hand feature, and star six ca…
  • and
  • mute your line.
  • We
  • ask that you please limit yourself to one question this morning. We will wait one moment t…

Questions & answers

Speaker 4

Unverified voice label

Good morning and thanks for taking the question. David, I I can't help but to think that on November 1st, 2006, 20 years ago, CBS and CareMark came together. I know you were ahead of sales at CAREMARC at the time, so I'm sure that this is a very important date for you. But can we first start with just the timing of this and the rationale?

You walked through a number of the components, but if we could just maybe maybe better understand especially the timing aspect.

Passages & reports (2)
  • Good morning and thanks for taking the question. David, I I can't help but to think that o…
  • we first start with just the timing of this and the rationale? You walked through a number…

Speaker 5

Unverified voice label

Um

Passages & reports (1)
  • Um

Speaker 2

sure. So and Lisa, good uh good to hear from you. And yes, I I do remember 20 years ago um in um in 2006 talking ?about what we were trying to build as a very different you know pharmacy services uh company and incredibly proud of the work that we've done over the last 20 years. And as I reflect back on on um on that I ?I can't help but think how much has changed since 2006 to 2026.

So 20 years of change, and even quite frankly,
?the change that we've seen from the timing of the acquisition of Vetna. So the market continues to evolve and change. And as a company, we need to continue to evolve with it. So in the two years of being in this position, um, I've been afforded the unique opportunity of actually thinking about this from a position of strength.

It's eight quarters of both a beat and raise, and a financial or balance sheet that is on this ahead of schedule in terms of its leverage. So we're we just we're afforded different decisions based off of the strength of the business. And I think there's two important things that
I would point to. One ?is the most of the energy over the last two years has been focusing on the Medicare recovery.

Um, and we're now entering our third year of that um that important um transition. And I think you'll hear a lot of that today. But I think that actually sets the stage for the fact that we
actually have what we think is a repeatable process to be able to compete effectively in that market. One thing we haven't talked a lot about is the progress that we've made at um at retail.

And with Prem leading the recovery effort from a business that was guiding negative five two years ago to
now we're we're guiding our third year of growth in that business. It just creates an opportunity for say what is the future of this business? How should we be organized to be able to compete effectively? And I think what we look for is the integration that matters and what we've done the last two years is integrate, ?you know, quite a bit inside of CBS Health with both CAREMARC and Aetna and some of the healthcare delivery assets that's helping us lean into value-based care.

But retail,
?you know, has for the most part, for the last two decades, operated behind a firewall. So we've always had to negotiate at arm's length. This run independent of the business. And I think that the timing of this decision is saying, you know, now is the time because we're not doing anything out of a distressed decision. We actually are doing it it because we actually have healthy balance sheets with appropriate calp out capital allocation opportunities and momentum in each one of the businesses that we're operating.

So again, I feel really good about the timing. I feel really good about the decision and I feel equally as important
about the team that's going to allow us to execute against this plan.

Passages & reports (20)
  • sure. So and Lisa, good uh good to hear from you. And yes, I I do remember 20 years ago um…
  • about
  • what we were trying to build as a very different you know pharmacy services uh company and…
  • I
  • can't help but think how much has changed since 2006 to 2026. So 20 years of change, and e…
  • the
  • change that we've seen from the timing of the acquisition of Vetna. So the market continue…
  • a position of strength. It's eight quarters of both a beat and raise, and a financial or b…
  • I would point to. One
  • is
  • the most of the energy over the last two years has been focusing on the Medicare recovery.…
  • actually have what we think is a repeatable process to be able to compete effectively in t…
  • now we're we're guiding our third year of growth in that business. It just creates an oppo…
  • two years is integrate,
  • you
  • know, quite a bit inside of CBS Health with both CAREMARC and Aetna and some of the health…
  • you
  • know, has for the most part, for the last two decades, operated behind a firewall. So we'v…
  • distressed decision. We actually are doing it it because we actually have healthy balance …
  • about the team that's going to allow us to execute against this plan.

Speaker 4

David, if I can sneak one more in just um on the quarter and on uh Brian's comments on 2027 and that's 340 B. I I understand it's it's incorporated in the way you're thinking about 27, but really just want to understand two things. One, is this a change in the way that you're contracting? And two, um, Ryan made the comment that you have line of sight, that it ends in 27, it doesn't spill into to 28.

Can you maybe just help me to understand that um when I when I think about
?you know what what's happening here and and why you have line of sight that that it's only going to have an impact here in 26 and 27?

Passages & reports (4)
  • David, if I can sneak one more in just um on the quarter and on uh Brian's comments on 202…
  • contracting? And two, um, Ryan made the comment that you have line of sight, that it ends …
  • you
  • know what what's happening here and and why you have line of sight that that it's only goi…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

it's a great question, Lisa. And I know there's been a lot of topics since our last earnings call on 340B, which is why we tried to size ?it as we head into on to 27. So maybe I'll have Brian speak a little bit ?about how we're thinking about HSS and then specifically 340B. And then I want to have Prem um speak a little bit to how we have our arms around and how we're thinking about specifically the 340B business.

So Brian? Sure. Thanks,

Passages & reports (5)
  • it's a great question, Lisa. And I know there's been a lot of topics since our last earnin…
  • it
  • as we head into on to 27. So maybe I'll have Brian speak a little bit
  • about
  • how we're thinking about HSS and then specifically 340B. And then I want to have Prem um s…

Speaker unclear

?David. And uh Lisa, thanks for the question.

Passages & reports (1)
  • David. And uh Lisa, thanks for the question.

Speaker 5

Um as I as I think

Passages & reports (1)
  • Um as I as I think

Speaker unclear

?think about the

Passages & reports (1)
  • think about the

Speaker 3

quarter itself, and then I'll progress on to 27. ?Uh performance in HSS, Lisa, was in line with our expectations. And you asked specifically about PS and 340B, both 340B and rebate guaranteed performance. We saw no surprises from our expectations. So we also continue to see strong performance in specialty in the quarter. We maintained our guide for the full year, so not expecting any surprises balance a year.

I'll comment since it's in the segment.

Passages & reports (4)
  • quarter itself, and then I'll progress on to 27.
  • Uh
  • performance in HSS, Lisa, was in line with our expectations. And you asked specifically ab…
  • so not expecting any surprises balance a year. I'll comment since it's in the segment.

Speaker 3

Street perform uh quite well. As we thought about next year, Lisa, and looking ahead to 27, uh, I thought it was important to establish a floor uh for the HS segment, and that's effectively what we've done today. We're we're we're confident that we would deliver at least 7 billion in HSS uh AOI next year. Uh that includes uh the discussions around year-over-year decline in 340 B next year uh and the impact of of lower care mark membership, those two elements.

And and so it also includes Tailwind's continued strength and specialty as well as the second year of improvement in HCD as we make progress towards
our path to profitability at Oak Street, et cetera. So confident in our ability to manage the near term dynamics, Lisa, and expect 27, as I mentioned previously, to reflect troth earnings for the segment as we return to growth in 27 as we look downward.

So Prem, you want to colour that up? Yeah,
thank thanks, Brian and David. And first off,

Passages & reports (4)
  • Street perform uh quite well. As we thought about next year, Lisa, and looking ahead to 27…
  • next year. Uh that includes uh the discussions around year-over-year decline in 340 B next…
  • our path to profitability at Oak Street, et cetera. So confident in our ability to manage …
  • thank thanks, Brian and David. And first off,

Speaker 5

thank you for the ?opportunity to lead CVS

Passages & reports (3)
  • thank you for the
  • opportunity to
  • lead CVS

Speaker 3

Pharmacy upon separation. it's an incredible opportunity. And just want to thank David and the board for that. When you when you think about the HSS segment, you know, the as Brian said, pharmacy services was in the quarter, was in line with our expectations, and we continue to feel good about our outlook for the remainder of the year. ?Um, as you look into 2027, we're also confident in our position and our ability to manage through the transitory dynamics that we discussed prior.

And you know, coming out of the last call, I think there's two areas: 340B was one, and the selling season was a second that I want to take a few
minutes to really spend a little bit more time on. So, with respect to 340B, we do not expect this to be a topic we need to discuss going forward. The level of contribution that we have ?in our 2027 plan is an even smaller portion of the HSS segment earnings than it has been historically.

And I would also reiterate that the it's an important program relied on by safety net hospitals and covered entities across the country. And we don't expect the program to go away fully in the future. Secondly,
when you look at the 2028 selling season we're headed into the season with confidence if you look at what the value proposition for care mark has and has always been it really starts with our industry leading cost of goods our customer focus and our sophisticated sophisticated capabilities ?and our pricing model flexibility that we offer to our customers um that it really address their top concerns and priorities which is affordability transparency and experience recall that 2026 for care mark was an incredibly strong selling season We achieved approximately $6 billion of gross new wins. ?

And
as Brian said, a portion of the membership declines we expect in 2027 reflect strategic business decisions ?from our health plan clients, including what you saw in Aetna's PDP book, which are not a reflection of CareMark's offerings that we ?have in the marketplace. ?And we expect the 2028 sales season and the new business pipeline to be robust ?and remain confident in our position and the value proposition that we're providing into the marketplace.

And finally, we have an incredibly strong and robust CVS specialty pharmacy business that's focused on the patients that we serve, but more importantly, the payers that we serve. Specialty continues to be a main driver of cost trend for
our customers. We continue very uh diligent in driving competition and creating value for our payer partners. And it's an area that we've invested a lot in technology and AI.

We continue to make the consumer experiences seamless. We continue to really drive an integrated and a very strong offering there for the patients that
we serve. So overall, I would I would just summarize this with we expect 2027 ?to represent trough earnings of at least the 7 billion and for our health services segment. And we're going to return to growth thereafter.

Passages & reports (24)
  • Pharmacy upon separation. it's an incredible opportunity. And just want to thank David and…
  • the remainder of the year.
  • Um,
  • as you look into 2027, we're also confident in our position and our ability to manage thro…
  • minutes to really spend a little bit more time on. So, with respect to 340B, we do not exp…
  • in
  • our 2027 plan is an even smaller portion of the HSS segment earnings than it has been hist…
  • when you look at the 2028 selling season we're headed into the season with confidence if y…
  • and
  • our pricing model flexibility that we offer to our customers um that it really address the…
  • And
  • as Brian said, a portion of the membership declines we expect in 2027 reflect strategic bu…
  • from
  • our health plan clients, including what you saw in Aetna's PDP book, which are not a refle…
  • have
  • in the marketplace.
  • And
  • we expect the 2028 sales season and the new business pipeline to be robust
  • and
  • remain confident in our position and the value proposition that we're providing into the m…
  • our customers. We continue very uh diligent in driving competition and creating value for …
  • we serve. So overall, I would I would just summarize this with we expect 2027
  • to
  • represent trough earnings of at least the 7 billion and for our health services segment. A…

Speaker 0

Your next question will come from the line of Justin Lake with Wolf Research. Please unmute your line and ask your question.

Passages & reports (1)
  • Your next question will come from the line of Justin Lake with Wolf Research. Please unmut…

Speaker unclear

?Thanks.

Passages & reports (1)
  • Thanks.

Speaker 5

Good morning. Uh, wanted to understand the impact of the breakup on the balance sheet and capital deployment

Passages & reports (1)
  • Good morning. Uh, wanted to understand the impact of the breakup on the balance sheet and …

Speaker 6

Unverified voice label

opportunities. Specifically, I assume the rating agencies are now going to look at CVS Health as a managed care organization, meaning debt to cap versus debt to EBADA. Wanted to hear how this might impact your leverage versus today. And then we've all been expecting significant share repo into 2027 and beyond. Is there any impact on the company's ability to deploy capital versus that $35 billion of deployable capital opportunity you discussed with the investor day, kind of post the breakup.

Thanks.

Passages & reports (2)
  • opportunities. Specifically, I assume the rating agencies are now going to look at CVS Hea…
  • impact on the company's ability to deploy capital versus that $35 billion of deployable ca…

Speaker unclear

?Yeah.

Passages & reports (1)
  • Yeah.

Speaker 2

So thanks, Justin. I'll um I'm going to let Brian speak to this, but I I I do want to just remind everybody ?that as we split CVS pharmacy, the expectations that we will have um solid investment grade positions on both of these these companies. And I it speaks to the strength ?of each one of the businesses that remain in our confidence in the balance sheet and the ability to have the appropriate cap capital allocation flexibility.

So Ryan, you want to

Passages & reports (5)
  • So thanks, Justin. I'll um I'm going to let Brian speak to this, but I I I do want to just…
  • that
  • as we split CVS pharmacy, the expectations that we will have um solid investment grade pos…
  • of
  • each one of the businesses that remain in our confidence in the balance sheet and the abil…

Speaker unclear

?Yeah, thanks, David. And uh

Passages & reports (1)
  • Yeah, thanks, David. And uh

Speaker 3

Justin, it's it's a good question. And uh obviously I've spent a lot of time uh on the leverage both together and some of the parts as we think about the business.

Passages & reports (1)
  • Justin, it's it's a good question. And uh obviously I've spent a lot of time uh on the lev…

Speaker 5

And ?I I I can say with a high degree of confidence that both companies will be solid investment grade with strong free cash flow generation. As you mentioned, we'll target leverage or debt to cap uh metrics that are appropriate for for that rating level. We'll bring you along on the process, Justin, as we move throughout the next 15, 18 months. You asked about share repo as well. ?

And
I can I can tell you we we we we basically have a history of of generating cash. You saw that in the guy we raised our cash $4 billion and my expectation to get back into the market here in the fourth quarter with the share repo program. So as we think about restoring that that leverage ratio and targets, were ahead of schedule.

As I look look out to the future and the transaction, uh, I wouldn't see anything getting in the way of our ability to deploy capital going forward.

Passages & reports (7)
  • And
  • I
  • I I can say with a high degree of confidence that both companies will be solid investment …
  • throughout the next 15, 18 months. You asked about share repo as well.
  • And
  • I can I can tell you we we we we basically have a history of of generating cash. You saw t…
  • that that leverage ratio and targets, were ahead of schedule. As I look look out to the fu…

Speaker 0

Your next question will come from the line of Michael Cherney with Lear Inc. Partners. Please unmute and ask your question.

Passages & reports (1)
  • Your next question will come from the line of Michael Cherney with Lear Inc. Partners. Ple…

Speaker unclear

?Uh good morning, and thank you for taking the question.

Passages & reports (1)
  • Uh good morning, and thank you for taking the question.

Speaker 7

Unverified voice label

Maybe to

Passages & reports (1)
  • Maybe to

Speaker 3

dive a

Passages & reports (1)
  • dive a

Speaker 7

little bit on future co. As you think about the business, there's clearly been numerous instances where CVS Pharmacy and CareMark made each other better. I'm thinking of ?the expansion and creation of maintenance choice among other different areas. How do you think about the potential? ?I don't want to call them dissergies specifically, but the strategic rationale for the overlap going forward between the two entities and who is and how that ?the competitive differentiation that both entities have been able to generate by being together, by being aligned between the store and the PBM, that they don't lose that capability going forward.

Passages & reports (7)
  • little bit on future co. As you think about the business, there's clearly been numerous in…
  • the
  • expansion and creation of maintenance choice among other different areas. How do you think…
  • I
  • don't want to call them dissergies specifically, but the strategic rationale for the overl…
  • the
  • competitive differentiation that both entities have been able to generate by being togethe…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

it's a great

Passages & reports (1)
  • it's a great

Speaker 3

question, Michael,

Passages & reports (1)
  • question, Michael,

Speaker 2

and something we've given quite a bit of thought to because ?we do think that there's something unique between CVS and CareMarket, even the role that Aetna plays in terms of engaging the pharmacist in the delivery of care. But the unique products that we've built over the last 20 years are things that were going to be preserved in commercial agreements between the two organizations.

So
we don't need the integration of in an operating structure. We need to make sure that we're aligned around where we believe that there can be value creation and make sure that there's an appropriate commercial agreement in place to support that. So that is in large part what we will be working on over the course of the next 15 to 18 months, is why the mail service is actually inside of CVS pharmacy because we have reinvented how pharmacy is delivered.

So it's not the traditional mail order and retail. It is basically a 90 day supply focused and organized around how the consumer wants to get their
medication. So we can choose ?to deliver it to the home. We can, they can pick it up in the store, they can come through something maybe as convenient as a drive-thru. But the idea is that we're organizing pharmacy around the consumer.

And the care market gets the benefit of partnering with a company like CVS Pharmacy that continues to
push the envelope on ways in which to better engage the consumer. ?The thing that we've spent more time on as opposed to the products that we built in the past is where we're going in the future. And that is ?the emphasis around the technology platform of Health 100.

It will be the connective tissue between the two organizations because CVS

Passages & reports (13)
  • and something we've given quite a bit of thought to because
  • we
  • do think that there's something unique between CVS and CareMarket, even the role that Aetn…
  • we don't need the integration of in an operating structure. We need to make sure that we'r…
  • the course of the next 15 to 18 months, is why the mail service is actually inside of CVS …
  • medication. So we can choose
  • to
  • deliver it to the home. We can, they can pick it up in the store, they can come through so…
  • push the envelope on ways in which to better engage the consumer.
  • The
  • thing that we've spent more time on as opposed to the products that we built in the past i…
  • the
  • emphasis around the technology platform of Health 100. It will be the connective tissue be…

Speaker 3

pharmacy becomes the engagement

Passages & reports (1)
  • pharmacy becomes the engagement

Speaker 2

engine. It's the most heavily transacted healthcare service. Um, and as a result, more frequent transactions and a higher engagement rate with the consumer. ?And what Aetna and CAREMARC bring to the table is all the financial information to help make more informed and better decisions around their healthcare. So you connect those two, which both organizations are committed to. And we think we will build a world-class consumer engagement platform to be able to help take advantage of where we believe and see technology going and also being able to democratize the data that we know is an important part of where healthcare is headed. ?

So
I think the most important takeaway is that we've given a lot of thought about what's unique that can that needs to be organized a certain way, which is why mail services at CBS retail. And it's why we need to focus on the commercial agreement so we have the sustainability and the durability of being able to continue to organize and service the uh you know the consumer.

Passages & reports (7)
  • engine. It's the most heavily transacted healthcare service. Um, and as a result, more fre…
  • And
  • what Aetna and CAREMARC bring to the table is all the financial information to help make m…
  • we believe and see technology going and also being able to democratize the data that we kn…
  • So
  • I think the most important takeaway is that we've given a lot of thought about what's uniq…
  • being able to continue to organize and service the uh you know the consumer.

Speaker 0

Next question will come to the line of Elizabeth Anderson with Evercore ISI. Please unmute and ask your question.

Passages & reports (1)
  • Next question will come to the line of Elizabeth Anderson with Evercore ISI. Please unmute…

Speaker 4

Hi guys, good ?morning. Thanks so much for the question.

Passages & reports (3)
  • Hi guys, good
  • morning.
  • Thanks so much for the question.

Speaker unclear

?Um, maybe one for you, Prem. Um I appreciate that comment you

Passages & reports (1)
  • Um, maybe one for you, Prem. Um I appreciate that comment you

Speaker 2

gave about sort of the the the

Passages & reports (1)
  • gave about sort of the the the

Speaker unclear

?the ability for the new the two organizations

Passages & reports (1)
  • the ability for the new the two organizations

Speaker 2

to continue ?to work together going forward.

Passages & reports (3)
  • to continue
  • to work together going
  • forward.

Speaker unclear

?Um Prem, where do you see sort of additional opportunities or

Passages & reports (1)
  • Um Prem, where do you see sort of additional opportunities or

Speaker 6

additional sort

Passages & reports (1)
  • additional sort

Speaker unclear

?of areas you could focus on for um

Passages & reports (1)
  • of areas you could focus on for um

Speaker 6

for the stores

Passages & reports (1)
  • for the stores

Speaker unclear

?going forward as an independent um entity that were not, you know, available to you sort of in the current

Passages & reports (1)
  • going forward as an independent um entity that were not, you know, available to you sort o…

Speaker 4

form?

Passages & reports (1)
  • form?

Speaker unclear

?Um and then two, maybe David, could you just comment on um where

Passages & reports (1)
  • Um and then two, maybe David, could you just comment on um where

Speaker 6

you see sort of trend overall? You talked about obviously pockets of strength in MA,

Passages & reports (1)
  • you see sort of trend overall? You talked about obviously pockets of strength in MA,

Speaker unclear

?but

Passages & reports (1)
  • but

Speaker 4

any more details you could provide on that to just continue

Passages & reports (1)
  • any more details you could provide on that to just continue

Speaker unclear

?to understand the improving strength there. Thank you very much. Yeah,

Passages & reports (1)
  • to understand the improving strength there. Thank you very much. Yeah,

Speaker 2

perfect. Thanks, Elizabeth. And let me um I'm gonna have Prem speak to where the future opportunities, but I think it's worth noting what we've done over the last two plus years to get ourselves in a position to go build new products and services and create new opportunities. So, Prem, if you could just take a second talking ?about your priority and why we're in a growth mode at retail and what what gives you confidence that we're gonna expand into new areas.

Passages & reports (4)
  • perfect. Thanks, Elizabeth. And let me um I'm gonna have Prem speak to where the future op…
  • take a second talking
  • about
  • your priority and why we're in a growth mode at retail and what what gives you confidence …

Speaker 3

Yeah, thanks, David and Elizabeth. Thank you for the question. This is an incredibly exciting time. And if you look ?at our retail business, if you look back, um, and I go back, you know, three or four years when we started to talk about the changes, the intentional changes that we're making here, um, historically, that was focused on really three things. First and foremost, we invested in the technology platform to create better experiences.

And if you think about just some clear examples, AI now supports our pharmacy workflow for 85% of our prescriptions. Second, we invested in our colleagues. We know that our 30,000 pharmacists, we know that our 200,000 store colleagues are essential components to deliver healthcare locally. And we know that healthcare is done by humans
in our local communities. And we ?have a tremendous focus on ensuring that our colleagues are enabled and successful in everything that they do.

And lastly, I think some of the things that we focused on around customer MPS. So the customers that walk in our stores, how do we really improve that experience for them? How do we make that omnichannel?
How do we make it consistent across the board? These are three areas we really spent a lot of time focusing on. And you can see that flow through in our results in this quarter, right?

As you saw in the quarter, our comp scripts uh grew 3.9%. But also, we were also able to
take advantage of new opportunities. ?I think GLP1s is another great example. ?Our scripts and GLP1s this quarter grew 23%. And it's because we took action, we made access more affordable, we made it easier for patients to show up. I mean, we really drove down uh the we really drove focus on what's most important ?for the people walking into our stores.

And then lastly, I think it's really important to talk about our evolution of the reimbursement model. We've focused on that over time with CVS cost managed. And you know, let me just be really clear: the CVS and CAREMARC relationships have operated behind a firewall for more than
?you know two decades. So this is something that we continually do, but we continue to be focused on the value proposition that we create to payers.

And as I look forward, I think the excitement I have in our CVS pharmacy asset is we have a well-run, strong service offering for the customers you serve.
We're in a position now to offer incremental healthcare services, leverage our 9,000 storage, leverage our footprint in very different ways. Because you know the key thing for most for almost all payers, I don't care who you are in this country, is we have a challenge with affordability. ?

And
CBS Pharmacy affords and has the privilege to serve in every community, standardize healthcare services and transform the industry in terms of what we can do. And this will afford us the right to to really drive this forward into the marketplace.

Passages & reports (20)
  • Yeah, thanks, David and Elizabeth. Thank you for the question. This is an incredibly excit…
  • at
  • our retail business, if you look back, um, and I go back, you know, three or four years wh…
  • And if you think about just some clear examples, AI now supports our pharmacy workflow for…
  • in our local communities. And we
  • have
  • a tremendous focus on ensuring that our colleagues are enabled and successful in everythin…
  • How do we make it consistent across the board? These are three areas we really spent a lot…
  • take advantage of new opportunities.
  • I
  • think GLP1s is another great example.
  • Our
  • scripts and GLP1s this quarter grew 23%. And it's because we took action, we made access m…
  • for
  • the people walking into our stores. And then lastly, I think it's really important to talk…
  • you
  • know two decades. So this is something that we continually do, but we continue to be focus…
  • We're in a position now to offer incremental healthcare services, leverage our 9,000 stora…
  • And
  • CBS Pharmacy affords and has the privilege to serve in every community, standardize health…

Speaker 2

That's perfect. So Pram is effectively running America's pharmacy. And we we say this all the time. We think this country needs uh CBS pharmacy and the community-based services that that we're providing because we are investing in the communities and we're going to continue to extend that reach as we um as we go forward. ?And now if I could just speak to the remaining CBS health organization and to Prem's point about this focus on affordability, we think the focus will now be purely on what we believe are the drivers of healthcare in this in this country.

And if you look at two-thirds of the spend coming from both
the health systems and the drug manufacturers, with increases that in most cases are high single or low double digits, there is ?a significant opportunity for this organization to tackle that challenge on behalf of the customers in which we serve. So we are declaring that the company that will remain will be focused to support the payers and bring affordability and improving access.

So, Steve, you want to just give a little bit of color on the
trend environment and how we're looking, maybe just on Medicare as an example. Sure. Um, so

Passages & reports (8)
  • That's perfect. So Pram is effectively running America's pharmacy. And we we say this all …
  • um as we go forward.
  • And
  • now if I could just speak to the remaining CBS health organization and to Prem's point abo…
  • the health systems and the drug manufacturers, with increases that in most cases are high …
  • a
  • significant opportunity for this organization to tackle that challenge on behalf of the cu…
  • trend environment and how we're looking, maybe just on Medicare as an example. Sure. Um, s…

Speaker 5

thanks, David.

Passages & reports (1)
  • thanks, David.

Speaker unclear

?Uh good morning,

Passages & reports (1)
  • Uh good morning,

Speaker 2

Elizabeth. So ?like Aetna

Passages & reports (3)
  • Elizabeth. So
  • like
  • Aetna

Speaker 5

has had a strong quarter as we talked about, uh really

Passages & reports (1)
  • has had a strong quarter as we talked about, uh really

Speaker unclear

?nice

Passages & reports (1)
  • nice

Speaker 2

progress across all the businesses ?at Aetna as we return the business to to target margins. But I'll just

Passages & reports (3)
  • progress across all the businesses
  • at
  • Aetna as we return the business to to target margins. But I'll just

Speaker unclear

?specifically comment on Medicare. You know, we we have seen some pockets of favorability, continues to be a high trend environment generally, but um, as we've laid down the foundation for this business over the last couple of

Passages & reports (1)
  • specifically comment on Medicare. You know, we we have seen some pockets of favorability, …

Speaker 6

years, ?we've seen tremendous improvement.

Passages & reports (3)
  • years,
  • we've
  • seen tremendous improvement.

Speaker unclear

?And we're gonna build on that. We took the same discipline indoor 2027 pricing pricing, assumed trends remained elevated, and and the priorities were were unchanged. We were going after uh one

Passages & reports (1)
  • And we're gonna build on that. We took the same discipline indoor 2027 pricing pricing, as…

Speaker 5

more ?year of of margin improvement. Um, and

Passages & reports (3)
  • more
  • year
  • of of margin improvement. Um, and

Speaker unclear

?we pulled

Passages & reports (1)
  • we pulled

Speaker 6

several

Passages & reports (1)
  • several

Speaker unclear

?levers to achieve

Passages & reports (1)
  • levers to achieve

Speaker 5

that. We obviously um uh is is as you ?could see, we we did ?make some adjustments to benefits, but beyond that, we made um adjustments to our geography, our product mix. We uh brought leading star scores into 2027 payment year. ?Um, we made adjustments to our networks. We had the highest performing providers in the markets where we wanted to perform. And and we uh we've built robust capabilities around medical cost management.

So
?all those levers we were able to put into place as we think about 2027. And just a little insight here early into AEP, but so far it's playing ?out exactly as we expected. We'll be able to get more color to that as we complete AEP. But uh this business is performing really well, and we expect another year of margin improvement with some modest growth, actually.

The benefit stability we're able to put into the marketplace is
?is, I think going to be uh important as we think about high retention of our current members. That helps engage the members, creates actually better healthcare costs and and a higher satisfaction. So so really like the position of the business, uh we have more work to do, still a high trend environment, but we're lining up a lot of capabilities at Aetna um with our investment in technology and the tools we're putting into place.

It's we really think we have an opportunity to impact the affordability and access issue that that is um so much needed in our
?in our healthcare

Passages & reports (16)
  • that. We obviously um uh is is as you
  • could
  • see, we we did
  • make some adjustments to
  • benefits, but beyond that, we made um adjustments to our geography, our product mix. We uh…
  • Um,
  • we made adjustments to our networks. We had the highest performing providers in the market…
  • all
  • those levers we were able to put into place as we think about 2027. And just a little insi…
  • out
  • exactly as we expected. We'll be able to get more color to that as we complete AEP. But uh…
  • is,
  • I think going to be uh important as we think about high retention of our current members. …
  • lining up a lot of capabilities at Aetna um with our investment in technology and the tool…
  • in
  • our healthcare

Speaker unclear

?system.

Passages & reports (1)
  • system.

Speaker 5

Thanks, Steve.

Passages & reports (1)
  • Thanks, Steve.

Speaker 2

Next question, operator.

Passages & reports (1)
  • Next question, operator.

Speaker 0

Next question will come from Aaron Wright with Morgan Stanley. Your line is now open. Please unmute and ask your question.

Passages & reports (1)
  • Next question will come from Aaron Wright with Morgan Stanley. Your line is now open. Plea…

Speaker unclear

?Hi, um, good morning. So can you speak to the rationale for retaining specialty at CVS Health and how you see the long term drivers and synergies playing out as also alongside kind of the

Passages & reports (1)
  • Hi, um, good morning. So can you speak to the rationale for retaining specialty at CVS Hea…

Speaker 6

PBM ?becomes more stable, more of a fee-for-service business over time. ?I guess do you see opportunities to further lean into specialty as that becomes a larger component of Romain Co or CVS Health?

Passages & reports (5)
  • PBM
  • becomes more stable,
  • more of a fee-for-service business over time.
  • I
  • guess do you see opportunities to further lean into specialty as that becomes a larger com…

Speaker unclear

?Yeah, it's a

Passages & reports (1)
  • Yeah, it's a

Speaker 5

great question, Aaron. ?And I think you're hearing

Passages & reports (3)
  • great question, Aaron.
  • And I
  • think you're hearing

Speaker unclear

?two things

Passages & reports (1)
  • two things

Speaker 2

from

Passages & reports (1)
  • from

Speaker 3

the remaining uh CVS Health organization. And that is the focus on affordability and access. And it also is the role that we play ?in trying to tackle those challenges for our customers. And Steve just talked a lot about Medicare. It is a growing part of the business as we have an aging population. And we believe that there is an important step from moving from a fee-for-service operating environment

Passages & reports (3)
  • the remaining uh CVS Health organization. And that is the focus on affordability and acces…
  • in
  • trying to tackle those challenges for our customers. And Steve just talked a lot about Med…

Speaker 2

to

Passages & reports (1)
  • to

Speaker 3

value-based care. So that piece is a heavy

Passages & reports (1)
  • value-based care. So that piece is a heavy

Speaker 2

investment for the business. And we

Passages & reports (1)
  • investment for the business. And we

Speaker 3

need

Passages & reports (1)
  • need

Speaker 2

to

Passages & reports (1)
  • to

Speaker 3

make sure we have the

Passages & reports (1)
  • make sure we have the

Speaker 2

appropriate

Passages & reports (1)
  • appropriate

Speaker 3

assets that create

Passages & reports (1)
  • assets that create

Speaker 2

the

Passages & reports (1)
  • the

Speaker 3

synergistic

Passages & reports (1)
  • synergistic

Speaker 2

and the

Passages & reports (1)
  • and the

Speaker 3

value prop for um for how we're going to tackle that those unique

Passages & reports (1)
  • value prop for um for how we're going to tackle that those unique

Speaker 2

high

Passages & reports (1)
  • high

Speaker 3

acuity populations. The same thing holds true on specialty. And we've talked for a long time. I I started um in 1993 with uh with care mark it was leading the part of how far how specialty

Passages & reports (1)
  • acuity populations. The same thing holds true on specialty. And we've talked for a long ti…

Speaker 2

integrates into the

Passages & reports (1)
  • integrates into the

Speaker 3

PBM. ?And if

Passages & reports (3)
  • PBM.
  • And
  • if

Speaker 2

I

Passages & reports (1)
  • I

Speaker 3

fast forward you

Passages & reports (1)
  • fast forward you

Speaker 2

know

Passages & reports (1)
  • know

Speaker 3

30

Passages & reports (1)
  • 30

Speaker 2

plus years later, you ?know, there is two percent of this population that's driving more than 50% of the spend of pharmacy. And it is growing at a rate that's not affordable and it's ?not sustainable. And so

Passages & reports (5)
  • plus years later, you
  • know,
  • there is two percent of this population that's driving more than 50% of the spend of pharm…
  • not
  • sustainable. And so

Speaker 3

it is why you need all of the levers of a classic PBM in order to continue to attack the um the rising drug cost and the way in which we create competition. And so we think the synergistic opportunity with the PBM especially

Passages & reports (1)
  • it is why you need all of the levers of a classic PBM in order to continue to attack the u…

Speaker 2

remains intact

Passages & reports (1)
  • remains intact

Speaker 3

because that is again one of the most important priorities for the customers that we're serving.

Passages & reports (1)
  • because that is again one of the most important priorities for the customers that we're se…

Speaker 2

And so that is part of the logic of keeping it

Passages & reports (1)
  • And so that is part of the logic of keeping it

Speaker 3

together.

Passages & reports (1)
  • together.

Speaker 2

And then

Passages & reports (1)
  • And then

Speaker 3

as

Passages & reports (1)
  • as

Speaker 2

I look specifically at the integration that matters, which I mentioned on the front end of the call, this has been a really interesting eight years in terms of bringing the businesses together. And what Aetna has has been able to gain through the um, you know, through the combination of the assets is a world-class PBM. So Aetna is far more sophisticated and far more effective in managing their pharmacy benefit

Passages & reports (2)
  • I look specifically at the integration that matters, which I mentioned on the front end of…
  • world-class PBM. So Aetna is far more sophisticated and far more effective in managing the…

Speaker 3

in addition to total cost of care because of the assets that CAREMARC and our specialty business brings to the table. And on the flip side of this, CAREMARC ?has been far more effective

Passages & reports (3)
  • in addition to total cost of care because of the assets that CAREMARC and our specialty bu…
  • has
  • been far more effective

Speaker 2

in terms of thinking about the role of pharmacy and how it impacts the total cost of care because it's outside of just ?the pharmacy benefit and is

Passages & reports (3)
  • in terms of thinking about the role of pharmacy and how it impacts the total cost of care …
  • the
  • pharmacy benefit and is

Speaker 3

the role that actually medications play in managing uh, you know, the the total cost of care, of which Aetna

Passages & reports (1)
  • the role that actually medications play in managing uh, you know, the the total cost of ca…

Speaker 2

is managing the total

Passages & reports (1)
  • is managing the total

Speaker 3

risk. ?So there has been a

Passages & reports (3)
  • risk.
  • So
  • there has been a

Speaker 2

really interesting and I think evolving um integration opportunities between the businesses. And I expect that that will continue as we find new markets

Passages & reports (1)
  • really interesting and I think evolving um integration opportunities between the businesse…

Speaker 3

and new opportunities. And this is in large part delivered to both

Passages & reports (1)
  • and new opportunities. And this is in large part delivered to both

Speaker 2

our Medicare population and equally as important to the commercial platforms and franchises that we have across both Aetna and CAREMARC. And lastly, Medicaid becomes very complementary to the business because these are high risk populations and actually in markets

Passages & reports (1)
  • our Medicare population and equally as important to the commercial platforms and franchise…

Speaker 3

that complement the roles that we're

Passages & reports (1)
  • that complement the roles that we're

Speaker 2

playing with Medicare and even the providers that we're working with across commercial.

Passages & reports (1)
  • playing with Medicare and even the providers that we're working with across commercial.

Speaker 0

Next question. We'll come from the Stephen Baxter with Wells Fargo. Please unmute your line and ask your question.

Passages & reports (1)
  • Next question. We'll come from the Stephen Baxter with Wells Fargo. Please unmute your lin…

Speaker 2

Yeah, hi. Thanks. Um, so you've touched on the, I guess, the capital and strategic parts of this, but if we think purely a bit about the operating cost structure, we can look back to the original uh CARAMARC and CVS transactions or the more recent CVS etNet transactions and just see that ?you know operating cost synergies were a big part of the financial financial rationale of those deals.

I know it's early, but I guess how are you thinking about what the potential financial dissynergies could be and any color on whether you think they'll sit entirely in the newly created CVS pharmacy business or I guess shared
or allocated across the two businesses. Thank you.

Passages & reports (4)
  • Yeah, hi. Thanks. Um, so you've touched on the, I guess, the capital and strategic parts o…
  • you know
  • operating cost synergies were a big part of the financial financial rationale of those dea…
  • or allocated across the two businesses. Thank you.

Speaker unclear

?Yes,

Passages & reports (1)
  • Yes,

Speaker 2

let me start and I'll let Brian finish. So we obviously are contemplating some one-time

Passages & reports (1)
  • let me start and I'll let Brian finish. So we obviously are contemplating some one-time

Speaker 3

cost. Um, and so that has

Passages & reports (1)
  • cost. Um, and so that has

Speaker 2

been

Passages & reports (1)
  • been

Speaker 3

contemplated in our our guidance and how

Passages & reports (1)
  • contemplated in our our guidance and how

Speaker 2

we're thinking about the future, but we feel like these are all manageable. ?And as we look at the opportunities

Passages & reports (3)
  • we're thinking about the future, but we feel like these are all manageable.
  • And
  • as we look at the opportunities

Speaker 3

that we've been describing on today's call, we think this will more than offset some of those expenses. So, Brian, I don't

Passages & reports (1)
  • that we've been describing on today's call, we think this will more than offset some of th…

Speaker 2

know if you have anything else to add.

Passages & reports (1)
  • know if you have anything else to add.

Speaker 5

Yeah, thanks, David. I just, Stephen, I just offer that uh, ?you know, when we looked at the deal, the strategic value created by by taking this action is gonna far outweigh any disergies. As I look at the run rate AOI impact of any stranded or public company cost, ?uh as well as any one-time cost, uh that they're they're they're certainly manageable uh and in line with other transactions of this type.

So we're going to look to offset any run rate costs over time, including pursuing opportunities created by a simpler independent structure that David referenced earlier. It's as you said, it's early
in the process. So expect us to come back with more details as we progress through the separation. ?But I'm confident that we certainly can manage any dissynergies

Passages & reports (8)
  • Yeah, thanks, David. I just, Stephen, I just offer that uh,
  • you
  • know, when we looked at the deal, the strategic value created by by taking this action is …
  • uh
  • as well as any one-time cost, uh that they're they're they're certainly manageable uh and …
  • in the process. So expect us to come back with more details as we progress through the sep…
  • But
  • I'm confident that we certainly can manage any dissynergies

Speaker unclear

?there.

Passages & reports (1)
  • there.

Speaker 0

Next question will come from Andrew Mock with Barclays. Please unmute and ask your question.

Passages & reports (1)
  • Next question will come from Andrew Mock with Barclays. Please unmute and ask your questio…

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 0

good morning. Just wanted to make sure ?I understand your 2027 EPS outlook of 865 in the context of all of today's uh today's results and announcements. So given

Passages & reports (3)
  • good morning. Just wanted to make sure
  • I
  • understand your 2027 EPS outlook of 865 in the context of all of today's uh today's result…

Speaker unclear

?the 20 cent raise to this year's EPS guidance, it doesn't look like you're assuming much EPS contribution from the resumption of share repurchase in 2027. Can you help us understand that dynamic and whether there are

Passages & reports (1)
  • the 20 cent raise to this year's EPS guidance, it doesn't look like you're assuming much E…

Speaker 6

any ?other offsets ?embedded in the outlook, including breakup costs you might incur next year? Thanks.

Passages & reports (5)
  • any
  • other
  • offsets
  • embedded in the
  • outlook, including breakup costs you might incur next year? Thanks.

Speaker unclear

?Go

Passages & reports (1)
  • Go

Speaker 2

ahead, Brian.

Passages & reports (1)
  • ahead, Brian.

Speaker 5

Yeah, so um uh you're reading it right, which is we we took the the guide this year up 20 cents uh and effectively flowed that through. We had talked about an 844 floor next year. Uh so now it's 865, uh, rounded up a penny. So we're at 865 next year. That only assumes the offset of dilution in share repo. So as you can imagine, as cash is back, ?uh leverage is where we want it to be, ?uh, we've got some dry powder uh to to to leverage.

Uh so net net what's implied in the guide next year where we set a floor
?uh is just the offset evolution. Hopefully that answers your

Passages & reports (8)
  • Yeah, so um uh you're reading it right, which is we we took the the guide this year up 20 …
  • the offset of dilution in share repo. So as you can imagine, as cash is back,
  • uh
  • leverage is where we want it to be,
  • uh,
  • we've got some dry powder uh to to to leverage. Uh so net net what's implied in the guide …
  • uh
  • is just the offset evolution. Hopefully that answers your

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker 0

Next up will be Ann Hines with Mizuho. Your line is now open. Please unmute and ask your question.

Passages & reports (1)
  • Next up will be Ann Hines with Mizuho. Your line is now open. Please unmute and ask your q…

Speaker unclear

?Great, thank you. Um, I know that you said 2028

Passages & reports (1)
  • Great, thank you. Um, I know that you said 2028

Speaker 6

should ?be on the higher end of your range. You provided an investor day. ?Um, are you ready to give any kind of growth algorithms, whether on an operating income or EPS for the two new companies on a standalone basis. Thanks.

Passages & reports (5)
  • should
  • be on the
  • higher end of your range. You provided an investor day.
  • Um,
  • are you ready to give any kind of growth algorithms, whether on an operating income or EPS…

Speaker 2

Yeah, go ahead, Brian. We're not really guiding beyond 28 at this point. And and Brian, you

Passages & reports (1)
  • Yeah, go ahead, Brian. We're not really guiding beyond 28 at this point. And and Brian, yo…

Speaker 5

yeah, I I I would just uh I was thinking back to investor day and we set out a roadmap which was in the mid teens uh which gets us to the 2028 horizon where we're we're tracking well against that. We always talked about multiple paths to get there. I think the businesses are performing very well. We just took 26 up again. That's a dollar over where we started. ?

Uh,
we just put a floor in for 27. And I what by by signaling that we're going to be at the upper end uh in the upper end of mid-teens by 28. ?Uh, I just wanted to give the street confidence that we're on track uh to meet or exceed our expectations. But we'll come back to you uh on the February call and uh we'll talk more about the details around the 27 guide and that'll give you a firmer base.

Passages & reports (6)
  • yeah, I I I would just uh I was thinking back to investor day and we set out a roadmap whi…
  • performing very well. We just took 26 up again. That's a dollar over where we started.
  • Uh,
  • we just put a floor in for 27. And I what by by signaling that we're going to be at the up…
  • Uh,
  • I just wanted to give the street confidence that we're on track uh to meet or exceed our e…

Speaker 3

Yes, I mean this is all this ?all is a

Passages & reports (3)
  • Yes, I mean this is all this
  • all
  • is a

Speaker 2

timing issue.

Passages & reports (1)
  • timing issue.

Speaker 3

You know, we gave headwinds and tailwinds early, ?you know, last quarter than we normally do. And so we'll be back in February with more clarity.

Passages & reports (3)
  • You know, we gave headwinds and tailwinds early,
  • you
  • know, last quarter than we normally do. And so we'll be back in February with more clarity…

Speaker 2

And maybe

Passages & reports (1)
  • And maybe

Speaker 3

just a reminder in case people are questioning this, this we are doing this out of a position of strength. We don't have to make the decisions. And

Passages & reports (1)
  • just a reminder in case people are questioning this, this we are doing this out of a posit…

Speaker 2

so as we're

Passages & reports (1)
  • so as we're

Speaker 3

looking at ?the business and how it's performing, we have confidence.

Passages & reports (3)
  • looking at
  • the
  • business and how it's performing, we have confidence.

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 2

we're actually doing this because we believe

Passages & reports (1)
  • we're actually doing this because we believe

Speaker 3

this is the right thing to do for the long-term growth of um of the business, not because there's any issue that may be

Passages & reports (1)
  • this is the right thing to do for the long-term growth of um of the business, not because …

Speaker 2

um on the horizon in 28.

Passages & reports (1)
  • um on the horizon in 28.

Speaker 0

Next question will come from Scott Fidel with Goldman Sachs. Please unmute and ask your question.

Passages & reports (1)
  • Next question will come from Scott Fidel with Goldman Sachs. Please unmute and ask your qu…

Speaker unclear

?Hi, thanks. Um, good

Passages & reports (1)
  • Hi, thanks. Um, good

Speaker 5

morning. Um, why ?don't you just go back to um the the margin improvement

Passages & reports (3)
  • morning. Um, why
  • don't you just go
  • back to um the the margin improvement

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 6

expansion um that's been uh been uh sustaining over at Aetna and and where you are specifically in that journey. ?Um clearly Medicare Advantage being the particular driver of that. And it seems like

Passages & reports (3)
  • expansion um that's been uh been uh sustaining over at Aetna and and where you are specifi…
  • Um
  • clearly Medicare Advantage being the particular driver of that. And it seems like

Speaker 5

at this ?point, um, based on your updated guidance, you probably breached into getting

Passages & reports (3)
  • at this
  • point,
  • um, based on your updated guidance, you probably breached into getting

Speaker 6

towards, ?I would think,

Passages & reports (3)
  • towards,
  • I would
  • think,

Speaker 5

sort of a very low level of profitability back in the Medicare Advantage business um for 2026 inside of the guidance. Just wanted to confirm that.

Passages & reports (1)
  • sort of a very low level of profitability back in the Medicare Advantage business um for 2…

Speaker unclear

?And then

Passages & reports (1)
  • And then

Speaker 6

I know Steve, you mentioned

Passages & reports (1)
  • I know Steve, you mentioned

Speaker 5

how, you know, I think he sent, you know, another one more year of of um, you know, uh sort of you know, focused um uh sort of margin improvement targeted for 27. Um, should I read into that anything in terms of where you expect to take the margins for uh for 27 back towards target or is this still a multi-year journey in terms of you know getting back to that three to four percent target margin for Medicare advantage?

Thanks.

Passages & reports (2)
  • how, you know, I think he sent, you know, another one more year of of um, you know, uh sor…
  • towards target or is this still a multi-year journey in terms of you know getting back to …

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 2

Steve.

Passages & reports (1)
  • Steve.

Speaker 5

Sure. Thanks.

Passages & reports (1)
  • Sure. Thanks.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

I

Passages & reports (1)
  • I

Speaker unclear

?can

Passages & reports (1)
  • can

Speaker 5

confirm uh the business is on still on its multi-year journey, um, but it's ahead of expectations. We ?are um moving into the profitable territory in 2026. So I can confirm that. Um and then ?as we to 27, we're gonna expand on that for the reasons I indicated earlier. Um, ?just a maybe a couple more thoughts as we think about uh the the business and and why we're so confident in the margin expansion 27. ?

Uh
beyond the the levers that I talked about, um I the uh repositioning of sort of the holistic Medicare. So as we think about our Part D standalone was performing well, we did a reset there. That's gonna contribute our group Medicare Vantage business. Um, we talked about that as we got through 2027, we would be ?uh we would have about 75% of the book repriced.

That's very much on track. Um, and so holistically, as you think about it, um, and and then and then as I said, um, we were able to add stability. So we'll be able to see some modest growth in the areas that we want to
see that growth. And so all this kind of comes together just just as we hoped and it's uh ?and we planned for and strong execution by the team and so really proud of where we are.

It's positioned nicely to go into 2027 with uh another year of nice margin expansion. Great.

Passages & reports (15)
  • confirm uh the business is on still on its multi-year journey, um, but it's ahead of expec…
  • are
  • um moving into the profitable territory in 2026. So I can confirm that. Um and then
  • as
  • we to 27, we're gonna expand on that for the reasons I indicated earlier. Um,
  • just
  • a maybe a couple more thoughts as we think about uh the the business and and why we're so …
  • Uh
  • beyond the the levers that I talked about, um I the uh repositioning of sort of the holist…
  • we got through 2027, we would be
  • uh
  • we would have about 75% of the book repriced. That's very much on track. Um, and so holist…
  • see that growth. And so all this kind of comes together just just as we hoped and it's uh
  • and
  • we planned for and strong execution by the team and so really proud of where we are. It's …

Speaker 2

Thanks, Steve. All right, operator. I think we have time for one more question.

Passages & reports (1)
  • Thanks, Steve. All right, operator. I think we have time for one more question.

Speaker 0

Okay, your last question will come from George Hill with DB. Please unmute and ask your question.

Passages & reports (1)
  • Okay, your last question will come from George Hill with DB. Please unmute and ask your qu…

Speaker unclear

?Uh yeah, thanks, guys. And I appreciate you taking the question. I I guess David just kind of round this out. I would ask as we think about the future split up, kind of what changed? And

Passages & reports (1)
  • Uh yeah, thanks, guys. And I appreciate you taking the question. I I guess David just kind…

Speaker 5

I guess

Passages & reports (1)
  • I guess

Speaker unclear

?could you talk a

Passages & reports (1)
  • could you talk a

Speaker 6

little bit more

Passages & reports (1)
  • little bit more

Speaker unclear

?about

Passages & reports (1)
  • about

Speaker 5

like what changed in the outlook in healthcare ?for from a year ago versus where you are now? And could you talk about like uh how you saw each business kind of like what was competitively disadvantaged and what becomes competitively advantaged through the split up? And I'll end it there. Thanks.

Passages & reports (3)
  • like what changed in the outlook in healthcare
  • for from a
  • year ago versus where you are now? And could you talk about like uh how you saw each busin…

Speaker 3

Yeah, George, thanks.

Passages & reports (1)
  • Yeah, George, thanks.

Speaker 2

Uh thanks for the question. Uh maybe I'll I'll end the way I started. Um, you know, two years ago when I ?when I took this job, we didn't have the ability to make decisions like this because we were struggling on our Medicare business. PCW was guiding down five

Passages & reports (3)
  • Uh thanks for the question. Uh maybe I'll I'll end the way I started. Um, you know, two ye…
  • when
  • I took this job, we didn't have the ability to make decisions like this because we were st…

Speaker 3

percent. And we were focused purely on running and operating this business against what we knew

Passages & reports (1)
  • percent. And we were focused purely on running and operating this business against what we…

Speaker unclear

?we

Passages & reports (1)
  • we

Speaker 2

were uh we were capable of of doing. And so I looked two years later, and the say do ratio that Brian has been so consistent on in terms of making sure that we that we that we underpromise and over-deliver. And we've been eight quarters of um of delivering on that. And so what's changed in two years is the fact that we now can look at this business and the assets that are assembled and really determine without any distress or without anything that we have to do on what is the right strategic decision to uh to make.

And so as we said, CBS Pharmacy has been
operating behind a firewall for the last two decades. It's always been an arm's length uh negotiation and and um and and um and structure, which again just reinforces the fact that there are integration opportunities, but nothing that we can't solve for with the commercial agreement. But what's powerful and where we see healthcare going is in the area of technology.

And so, how do we make sure that we capitalize on this next wave of change that we know is is gonna is going to
?be very prevalent inside the healthcare space and make sure we we leverage everything that we actually have in this current enterprise and preserve it for uh for the future. That's why we're spending as much time on connecting and integrating where we believe it matters.

And so we're preserving the CVS

Passages & reports (6)
  • were uh we were capable of of doing. And so I looked two years later, and the say do ratio…
  • changed in two years is the fact that we now can look at this business and the assets that…
  • operating behind a firewall for the last two decades. It's always been an arm's length uh …
  • going is in the area of technology. And so, how do we make sure that we capitalize on this…
  • be
  • very prevalent inside the healthcare space and make sure we we leverage everything that we…

Speaker 3

and Aetna

Passages & reports (1)
  • and Aetna

Speaker 2

um integration. We're preserving the Oak Street and um in Aetna uh Signify. Um, and we're also now focusing on on areas that uh that we know we can capitalize in the future around um around technology. So ?um I would just say, ?you know, I couldn't be happier and more proud of the team's performance that led us to a place where we can make the decisions out of um you know out of strength.

And also the fact that um, you know, that we uh that we believe this is the right thing for all stakeholders involved. We
were gonna we believe we're gonna serve our consumers more effectively, we're gonna serve our customers more effectively, and hopefully that will actually be viewed favorably from the shareholders that are investing in this company. So I just I just in closing, I just want to thank everyone for joining this morning.

Um we're incredibly
excited about this next step in our evolution. I want to specifically thank our colleagues across the country and across this company that work in the work that they do every day to serve our customers. Their dedication and relentless commitment to those we serve has built the foundation for everything we've discussed today. We've taken this deliberate action to create long-term value and do even more to deliver on our purpose, to simplify health care in one person, one family, and one community at a time. ?

And
I look forward to keeping you updated on our progress.

Passages & reports (10)
  • um integration. We're preserving the Oak Street and um in Aetna uh Signify. Um, and we're …
  • um
  • I would just say,
  • you know,
  • I couldn't be happier and more proud of the team's performance that led us to a place wher…
  • were gonna we believe we're gonna serve our consumers more effectively, we're gonna serve …
  • excited about this next step in our evolution. I want to specifically thank our colleagues…
  • taken this deliberate action to create long-term value and do even more to deliver on our …
  • And
  • I look forward to keeping you updated on our progress.

Speaker 0

Thank you for joining CBS Health's third quarter 2026 earnings call. This concludes today's conference call. You may now disconnect.

Passages & reports (1)
  • Thank you for joining CBS Health's third quarter 2026 earnings call. This concludes today'…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 500. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T22:08:07.486Z.
Transcript version v1-7451d33cbb686a30a578 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.